Breaking News

Catalent Ups Stake in Redwood Bioscience

April 3, 2014

Catalent Pharma Solutions has increased its minority investment in Redwood Bioscience. The decision was based on data generated by the SMARTag ADC platform, a precision protein-chemical engineering platform and novel toxin-linker technology developed by Redwood to enable the generation of homogeneous antibody-drug conjugates (ADCs) engineered to enhance potency, safety and stability. Employing Redwood’s SMARTag ADC platform combined with Catalent’s GPEx cell line expression system, the companies recently completed a biomanufacturing Center of Excellence in Madison, WI, offering a range of analytical and fill-finish services.  
In April of last year, Catalent had acquired an exclusive license to market the SMARTag technology and has since collaborated with Redwood for the development and marketing of the technology. As part of the collaboration, Catalent took a minority equity stake in Redwood, which may increase over time and could lead to a potential acquisition.  

“The potential that we initially identified in the SMARTag technology has been borne out by the successful achievement of in vivo and in vitro proof of concept milestones, leading to our next phase of investment,” said Barry Littlejohns, president, Advanced Delivery Technologies. He added “These studies have further illustrated that our ongoing collaboration with Redwood will offer significant and differentiating value to our growing number of customers looking to develop next-generation ADC therapies.”   

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016